Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, ORIC Pharmaceuticals Inc’s stock clocked out at $9.9, up 2.48% from its previous closing price of $9.66. In other words, the price has increased by $2.48 from its previous closing price. On the day, 0.87 million shares were traded. ORIC stock price reached its highest trading level at $10.05 during the session, while it also had its lowest trading level at $9.67.
Ratios:
To gain a deeper understanding of ORIC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.13 and its Current Ratio is at 16.13. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on July 08, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
On October 31, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $20.
On September 06, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $20.Stifel initiated its Buy rating on September 06, 2024, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 01 ’25 when Piscitelli Dominic sold 20,000 shares for $10.05 per share. The transaction valued at 200,972 led to the insider holds 48,317 shares of the business.
Piscitelli Dominic sold 32,466 shares of ORIC for $341,039 on Jun 24 ’25. The Chief Financial Officer now owns 68,317 shares after completing the transaction at $10.50 per share. On Jun 23 ’25, another insider, Piscitelli Dominic, who serves as the Chief Financial Officer of the company, sold 1,034 shares for $10.00 each. As a result, the insider received 10,344 and left with 100,783 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORIC now has a Market Capitalization of 961517632 and an Enterprise Value of 495748960.
Stock Price History:
The Beta on a monthly basis for ORIC is 1.62, which has changed by 0.0040568113 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, ORIC has reached a high of $14.67, while it has fallen to a 52-week low of $3.90. The 50-Day Moving Average of the stock is -3.75%, while the 200-Day Moving Average is calculated to be 16.39%.
Shares Statistics:
It appears that ORIC traded 1.38M shares on average per day over the past three months and 771370 shares per day over the past ten days. A total of 86.19M shares are outstanding, with a floating share count of 40.86M. Insiders hold about 57.93% of the company’s shares, while institutions hold 62.80% stake in the company. Shares short for ORIC as of 1753920000 were 6758787 with a Short Ratio of 4.91, compared to 1751241600 on 12580266. Therefore, it implies a Short% of Shares Outstanding of 6758787 and a Short% of Float of 8.05.
Earnings Estimates
The dynamic stock of ORIC Pharmaceuticals Inc (ORIC) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.28 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.29 and -$2.53 for the fiscal current year, implying an average EPS of -$1.68. EPS for the following year is -$1.66, with 11.0 analysts recommending between -$1.03 and -$2.84.
